Celgene Corp. Receives “Buy” Rating from TheStreet (CELG)
Celgene Corp. (NASDAQ:CELG)‘s stock had its “buy” rating restated by investment analysts at TheStreet in a note issued to investors on Tuesday, Analyst Ratings Network reports.
The analysts wrote, “Celgene Corporation (CELG) has been reiterated by TheStreet Ratings as a buy with a ratings score of B. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
Celgene Corp. (NASDAQ:CELG) opened at 156.49 on Tuesday. Celgene Corp. has a 1-year low of $97.85 and a 1-year high of $174.66. The stock has a 50-day moving average of $163. and a 200-day moving average of $154.1. The company has a market cap of $64.161 billion and a P/E ratio of 46.47.
Celgene Corp. (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, January 30th. The company reported $1.51 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.54 by $0.03. The company had revenue of $1.76 billion for the quarter, compared to the consensus estimate of $1.72 billion. On average, analysts predict that Celgene Corp. will post $7.30 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Celgene Corp. in a research note on Tuesday, February 4th. They now have a $162.00 price target on the stock. Separately, analysts at Guggenheim cut their price target on shares of Celgene Corp. from $193.00 to $191.00 in a research note on Friday, January 31st. Finally, analysts at BMO Capital Markets raised their price target on shares of Celgene Corp. from $200.00 to $211.00 in a research note on Friday, January 31st. They now have an “outperform” rating on the stock. Two research analysts have rated the stock with a sell rating, three have given a hold rating and sixteen have issued a buy rating to the stock. Celgene Corp. has an average rating of “Buy” and a consensus price target of $176.14.
In other Celgene Corp. news, Director Ernest Mario sold 13,500 shares of the stock on the open market in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $151.87, for a total transaction of $2,050,245.00. Following the sale, the director now directly owns 100,671 shares in the company, valued at approximately $15,288,905. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.